Agenus Inc
NASDAQ:AGEN
Agenus Inc
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 441 full-time employees. The company went IPO on 2000-02-04. The company has a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Its I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy, vaccines and adjuvants. Its antibody candidates are Balstilimab (an anti-PD-1 antibody) and Zalifrelimab (an anti-CTLA-4 antibody), which is in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Its clinical-stage asset portfolio also includes Botensilimab (AGEN1181), AGEN2373, AGEN1423, AGEN1777, MK-4830, INCAGN2390, INCAGN2385 and AGENT 797. The company is developing personalized vaccines, namely Prophage and AutoSynVax, and off-the-shelf vaccines PhosphoSynVax, which contains heat shock proteins to deliver neoantigens to the right immune cells to activate an anti-cancer immune response.
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 441 full-time employees. The company went IPO on 2000-02-04. The company has a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Its I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy, vaccines and adjuvants. Its antibody candidates are Balstilimab (an anti-PD-1 antibody) and Zalifrelimab (an anti-CTLA-4 antibody), which is in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Its clinical-stage asset portfolio also includes Botensilimab (AGEN1181), AGEN2373, AGEN1423, AGEN1777, MK-4830, INCAGN2390, INCAGN2385 and AGENT 797. The company is developing personalized vaccines, namely Prophage and AutoSynVax, and off-the-shelf vaccines PhosphoSynVax, which contains heat shock proteins to deliver neoantigens to the right immune cells to activate an anti-cancer immune response.
Colorectal Cancer Crisis: Management described colorectal cancer as a rapidly escalating crisis, with rising deaths worldwide and a sharp increase among young adults.
BOT/BAL Immunotherapy: Agenus highlighted strong data for its BOT/BAL combination, with late-stage colorectal cancer patients showing a 42% two-year survival rate and median survival of 21 months, far above current standards.
Regulatory Delays: Executives and clinicians criticized regulatory hurdles, stating bureaucratic delays are preventing patients from accessing potentially life-extending treatments like BOT/BAL.
Phase III Trial Update: A pivotal Phase III trial for BOT/BAL, targeting patients with no remaining standard options, is about to launch across multiple countries, with rapid enrollment expected.
Zydus Manufacturing Deal: Agenus expects to close its manufacturing facility sale to Zydus soon, after clearing key regulatory hurdles, which will provide operational and cost advantages.
Financial Position: The company is pursuing further financing and partnership opportunities, with one significant cash infusion deal nearing completion.
Innovative Cell Therapy: Subsidiary MiNK is advancing iNKT cell therapies for cancer and infectious diseases, drawing interest from government agencies.
